BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SPH4336 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SPH4336\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05860465-9055@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SPH4336: Phase 2/3 readout est. (NCT05860465)
DESCRIPTION:SPH4336\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in
  the Treatment of Locally Advanced or Metastatic Breast Cancer\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sph4336#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05860465
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944224-9055@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SPH4336: Phase 1/2 readout est. (NCT05944224)
DESCRIPTION:SPH4336\, phase 1/2.\nStudy: A Study to Efficacy and Safety of 
 SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Ad
 vanced Solid Tumors.\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sph4336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05944224
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872347-9055@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SPH4336: Phase 2 readout est. (NCT05872347)
DESCRIPTION:SPH4336\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStudy:
  Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in B
 reast Cancer Patients With Brain Metastases.\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 ph4336#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05872347
URL:https://assetmemo.bio/drug/sph4336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
